Glucokinase (GK), which phosphorylates
D-glucose, is a major
glucose sensor in β-cells for
glucose-stimulated insulin secretion (GSIS) and is a promising new drug target for
type 2 diabetes (T2D). In T2D, pancreatic β-cells exhibit defective
glucose sensitivity, which leads to impaired GSIS. Although
glucagon-like peptide-1-(7-36)-amide (GLP-1) is known to enhance β-cell
glucose sensitivity, the effect of
GLP-1 on GK activity is still unknown. The present study demonstrated that
GLP-1 pretreatment for 30 min significantly enhanced GK activity in a
glucose-dependent manner, with a lower Michaelis-Menten constant (K(m)) but unchanged maximal velocity (V(max)). Thus,
GLP-1 acutely enhanced cellular
glucose uptake, mitochondrial membrane potential, and cellular
ATP levels in response to
glucose in rat INS-1 and native β-cells. This effect of
GLP-1 occurred via its
G protein-coupled receptor pathway in a cAMP-dependent but
protein kinase A-independent manner with evidence of exchange
protein activated by cAMP (
Epac) involvement. Silencing Epac2, interacting molecule of the
small G protein Rab3 (Rim2), or Ras-associated
protein Rab3A (Rab3A) significantly blocked the effect of
GLP-1. These results suggested that
GLP-1 can further potentiate GSIS by enhancing GK activity through the signaling of Epac2 to Rim2 and Rab3A, which is the similar pathway for
GLP-1 to potentiate Ca(2+)-dependent
insulin granule exocytosis. The present finding may also be an important mechanism of
GLP-1 for recovery of GSIS in T2D.